Actively Recruiting
Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II
Led by Fazaia Ruth Pfau Medical College · Updated on 2025-03-21
156
Participants Needed
1
Research Sites
87 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Effect of Empagliflozin on Quality of Life in patient of Chronic Heart Failure with Diabetes Mellitus Type II. As per ESC Guidelines Empagliflozin is recommended as part of the first-line treatment for HFrEF, irrespective of diabetes status. As per American College of Cardiology (ACC)/American Heart Association (AHA) Empagliflozin is recommended in both diabetic and non-diabetic HF (especially beneficial in patients with HFrEF and HFpEF). The aim of my study is to assess the impact of Empagliflozin on quality of life in Pakistani patients, considering the genetic, environmental and cultural factors. The study will also explore whether Empagliflozin can offer cost-effective option for managing chronic heart failure and diabetes, potentially reducing the economic burden on both patients and health care system.
CONDITIONS
Official Title
Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 40 to 70 years at time of screening
- Both men and women are eligible
- Chronic heart failure patients classified as class II-IV by NYHA with ejection fraction below 40%
- NT-proBNP levels greater than 25 pg/ml
- Diagnosed diabetes mellitus with HbA1c above 6.5 mg/dl and currently on antidiabetic medication
You will not qualify if you...
- Pregnant women
- Patients with end stage renal disease (ESRD)
- Patients with acute decompensated heart failure
- Patients with acute coronary syndrome
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fazaia Ruth Pfau Hospital
Karachi, Sindh, Pakistan, 75120
Actively Recruiting
Research Team
T
Tooba Riaz, MBBS
CONTACT
D
DR Asghar Mehdi, MBBS Phd
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here